Four-Drug attack on blood cancer shows promise in major trial
NCT ID NCT03710603
Summary
This study is testing whether adding a drug called daratumumab to a standard three-drug combination works better for people newly diagnosed with multiple myeloma, a cancer of plasma cells in the bone marrow. It will involve about 709 participants who are eligible for a stem cell transplant. The main goal is to see if the four-drug combination keeps the cancer from getting worse for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Hospital
Melbourne, Australia
-
Ankara University
Ankara, Turkey (Türkiye)
-
Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi Di Ancona
Ancona, Italy
-
CHRU Hôtel Dieu
Nantes, France
-
Erasmus MC
Rotterdam, Netherlands
-
Hospital Clinic I Provincial de Barcelona
Barcelona, Spain
-
Kantonsspital St. Gallen
Sankt Gallen, Switzerland
-
Odense University Hospital
Odense, Denmark
-
Oslo University Hospital
Oslo, Norway
-
Regional General Hospital Alexandra
Athens, Greece
-
University Hospital Leuven
Leuven, Belgium
-
University Hospital Ostrava
Ostrava, Czechia
-
Uniwersytet Jagiellonski Collegium Medicum
Krakow, Poland
Conditions
Explore the condition pages connected to this study.